Ocular Allergy

FDA approves Dextenza for ocular itching from allergic conjunctivitis

The FDA approved Ocular Therapeutix Inc.’s Supplemental New Drug Application (sNDA) that further extends Dextenza’s (dexamethasone ophthalmic insert) 0.4 mg indications, the company announced Monday.

VA and visual function go the way of ocular inflammation

Tool for quantifying measures may predict outcomes for patients.

FDA approves cyclosporine A eye drop for vernal keratoconjunctivitis

Most patients with allergic disorder are children, adolescents, or young adults.